BioSpace News Archive

Cryoport, Inc. announced that it intends to offer shares of common stock in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange Commission.

ArTara Therapeutics, a clinical-stage biopharmaceutical company developing treatments for rare diseases with significant unmet therapeutic needs, has initiated development of TARA-002, a toll-like receptor 4 agonist, for the potential treatment of lymphangiomas.

Intuitive Interface Gives Healthcare Provider A New Level Of Oversight Into Their Denials Data

Suketu Upadhyay Appointed Chief Financial Officer, Effective July 1, 2019, Succeeding Daniel Florin

Doctor Evidence, a global health technology and consulting company in biomedical research, releases new updates and an interactive user interface for the DOC Search platform on June 24th.

SERAXIS Inc. announces signing a research collaboration agreement with Wake Forest Baptist Health to further build on SERAXIS existing diabetes program.

Seven and Eight Biopharmaceuticals Inc. announced that it has signed a clinical research collaboration agreement with Roche to explore the combination of Seven and Eight’s BDB001, an immune modulator targeting toll-like receptors 7 and 8, and atezolizumab, a monoclonal antibody against the checkpoint target of PD-L1, in treating solid tumors.